Kemiras new production plant in Tarragona successfully started up
April 23, 2014 - London
April 23, 2014 at 8.30 am (CET+1)
Kemira Oyj has successfully started up production in its new coagulant plant located in Tarragona, Spain. The plant is able to produce the entire range of Kemira's aluminum and iron-based coagulants that are used for drinking water and wastewater treatment.
Kemira's plant is built on Bayer MaterialScience's site securing sustainable access to raw material in a long term partnership. Kemira utilizes in its coagulant production hydrochloric acid that is a co-product derived from Bayer MaterialScience's production of methylene biphenyl diisocyanate (MDI).
The new Tarragona plant will be one of largest combined coagulant manufacturing plants in EMEA. Polyaluminum chloride (PAX), Aluminum sulfate (ALS) and Ferric chloride (PIX) will all be produced at the site and the capacity is instrumental in sustaining Kemira's leadership position in the municipal and industrial water treatment market in EMEA.
"The integration of our production facility and the partnership with Bayer MaterialScience in Tarragona provides us with crucial economic and environmental benefits.And after the successful startup of the world scale coagulant plant in Dormagen, Germany last year, another major step is taken towards securing a competitive future with coagulants, in line with our strategy ", says Frank Wegener, President, SegmentMunicipal & Industrial, Kemira Oyj.
The Tarragona plant is also an important step in consolidating Kemira's manufacturing footprint for coagulants in EMEA.
For more information, please contact
Dr. Frank Wegener, President, Segment Municipal & Industrial
Tel. +49 69 256 1280
Leena Lie, SVP, Communications & Corporate Responsibility
Tel. +358 40 745 7943
Kemira is a global chemicals company serving customers in water-intensive industries. We provide expertise and chemicals that improve our customers' water, energy and raw material efficiency. Our focus is on pulp & paper, oil & gas, mining and water treatment. In 2013, Kemira had annual revenue of EUR 2.2 billion and around 4,500 employees. Kemira shares are listed on the NASDAQ OMX Helsinki Ltd.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kemira Oyj via Globenewswire